Teva Agrees To Sell Assets In $8.9B Merger With Barr
Teva Pharmaceutical Industries Ltd. has completed its $8.9 billion acquisition of rival Barr Pharmaceuticals Inc. after agreeing to sell competing products in 29 U.S. and 17 European markets for generic drugs....To view the full article, register now.
Already a subscriber? Click here to view full article